UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The Lancet (British edition), ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 229 - 240
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cyclophosphamide - administration & dosage | Prednisone - administration & dosage | Double-Blind Method | Humans | Middle Aged | Immunologic Factors - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Immunoconjugates - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Large-Cell, Anaplastic - drug therapy | Intention to Treat Analysis | Vincristine - administration & dosage | Adult | Female | Aged | Immunologic Factors - adverse effects | Brentuximab Vedotin | Doxorubicin - administration & dosage | Immunoconjugates - adverse effects | Leukemia | Clinical trials | Lymphocytes T | Peripheral neuropathy | Cancer therapies | Doxorubicin | Evidence-based medicine | Regulatory approval | Randomization | CD30 antigen | Safety management | Genetics | Safety | Active control | Neutropenia | Cell survival | Prednisone | Patients | Survival | Vincristine | Lymphoma | Cyclophosphamide | Chemotherapy | Medical prognosis | Adults | Interferon | Anaplastic large-cell lymphoma | T-cell lymphoma | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2006, Volume 7, Issue 5, pp. 379 - 391
Life Sciences & Biomedicine | Oncology | Science & Technology | Antibodies, Monoclonal, Murine-Derived | Prognosis | Humans | Lymphoma, B-Cell - diagnosis | Middle Aged | Antineoplastic Combined Chemotherapy Protocols | Rituximab | Antibodies, Monoclonal - therapeutic use | Survival Rate | Treatment Outcome | Antineoplastic Agents - therapeutic use | Prednisone | Doxorubicin | Vincristine | Disease-Free Survival | Cyclophosphamide | Adolescent | Adult | Lymphoma, B-Cell - drug therapy | Lymphoma, Non-Hodgkin - diagnosis | Lymphoma, Non-Hodgkin - drug therapy | Medical colleges | Chemotherapy | Anthracyclines | Corticosteroids | Clinical trials | Lymphomas | Cancer | Index Medicus | Medicin och hälsovetenskap
Journal Article
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 12, pp. 1250 - 1259
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Rituximab | Etoposide - administration & dosage | Male | Young Adult | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Antimitotic agents | Chemotherapy | Stem cells | Dosage and administration | Product development | Transplantation | Lymphomas | Antineoplastic agents | Cancer | Medical informatics | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 08/2019, Volume 125, Issue 15, pp. 2579 - 2586
inotuzumab | older acute lymphoblastic leukemia (ALL) | blinatumomab | outcome | mini‐hyperfractionated cyclophosphamide, vincristine, and dexamethasone (mini‐HCVD) | Life Sciences & Biomedicine | Oncology | Science & Technology | Inotuzumab Ozogamicin - therapeutic use | Inotuzumab Ozogamicin - pharmacology | Antibodies, Bispecific - pharmacology | Humans | Middle Aged | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Survival Rate | Antineoplastic Agents, Immunological - pharmacology | Antibodies, Bispecific - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Propensity Score | Antineoplastic Agents, Immunological - therapeutic use | Aged, 80 and over | Female | Aged | Dexamethasone | Acute lymphatic leukemia | Leukemia | Antibodies | Lymphatic leukemia | Multivariate analysis | Survival | Doxorubicin | Vincristine | Philadelphia chromosome | Matching | Cyclophosphamide | Chemotherapy | Medical prognosis | Remission | Chromosomes | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 05/2012, Volume 379, Issue 9828, pp. 1791 - 1799
Internal Medicine | Radiotherapy Dosage | Doxorubicin/adverse effects | Etoposide/adverse effects | Procarbazine/adverse effects | Prospective Studies | Hodgkin Disease/drug therapy | Humans | Middle Aged | Proportional Hazards Models | Male | Treatment Outcome | Positron-Emission Tomography | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Prednisone/adverse effects | Treatment Failure | Adolescent | Survival Analysis | Adult | Female | Cyclophosphamide/adverse effects | Vincristine/adverse effects | Neoplasm Staging | Bleomycin/adverse effects | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Doxorubicin - therapeutic use | Hodgkin Disease - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Hodgkin Disease - drug therapy | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - therapeutic use | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Histology | Radiation therapy | Lymphoma | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 05/2017, Volume 2017, Issue 5, pp. CD007941 - CD007941
Procarbazine | Vinblastine | Hodgkin Disease | Antineoplastic Combined Chemotherapy Protocols | Etoposide | Prednisone | Doxorubicin | Vincristine | Disease Progression | Randomized Controlled Trials as Topic | Dacarbazine | Hodgkin Lymphoma | Cyclophosphamide | Blood disorders | Bleomycin | Hodgkin’s lymphoma | Child health | Medicine General & Introductory Medical Sciences | Haematological malignancies | Cancer | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Young Adult | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - administration & dosage | Bleomycin - administration & dosage | Bleomycin - adverse effects | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - adverse effects | Doxorubicin - adverse effects | Index Medicus
Journal Article